Chemotherapy consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine with granulocyte-colony-stimulating factor in HIV-infected patients with newly diagnosed Hodgkin's disease: a prospective, multi-institutional AIDS Clinical Trials Group Study (ACTG 149)

Article Abstract:

HIV patients with Hodgkin's disease may benefit from chemotherapy with doxorubicin, bleomycin, vinblastine, and dacarbazine. In a study of 21 such patients, 62% had a complete or partial response to chemotherapy.

Care and treatment, Hodgkin's disease, HIV patients

---

High-dose cytosine-arabinoside and cisplatin regimens as salvage therapy for refractory or relapsed AIDS-related non-Hodgkin's lymphoma

Article Abstract:

A retrospective review of 26 patients with recurrent or primary resistant AIDS-related non-Hodgkin's lymphoma (AIDS-NHL) and treated with either dexamethasone, cytosine arabinoside, and cisplatin (DHAP) or etoposide, methylprednisolone, cytosine arabinoside and cisplatin (ESHAP) has been carried out. High-dose cytosine-arabinoside and cisplatin regimens are investigated as salvage therapy for refractory or relapsed AIDS-NHL. No effective salvage regimen had been set forth for those with AIDS-NHL not responding to first-line chemotherapy including anthracycline.

United States, Research, Evaluation, Diseases, Drug therapy, Lymphomas, AIDS (Disease), Recurrence (Disease), AIDS research

---

Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection

Article Abstract:

Low-dose m-BACOD chemotherapy appears to be as effective as standard-dose m-BACOD chemotherapy in the treatment of lymphomas and has fewer side effects. This was the conclusion of a study that randomly assigned 198 HIV-positive patients with non-Hodgkin's lymphoma to receive low-dose or standard-dose m-BACOD. m-BACOD consists of methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine and dexamethasone. Survival rates were similar in both groups but toxic effects were seen in only 51% of those in the low-dose group compared to 70% of those in the standard-dose group.

Complications and side effects, Non-Hodgkin's lymphomas, Dosage and administration

Similar abstracts:

• Abstracts: Micronutrient levels and HIV disease status in HIV-infected patients on highly active antiretroviral therapy in the nutrition for healthy living cohort
• Abstracts: Transient angiolymphoid hyperplasia and Kaposi's sarcoma after primary infection with human herpesvirus 8 in a patient with human immunodeficiency virus infection
• Abstracts: Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and those without HIV infection
• Abstracts: Chlamydial and gonococcal cervicitis in HIV-seropositive and HIV-seronegative pregnant women in Bangkok: prevalence, risk factors, and relation to perinatal HIV transmission
• Abstracts: Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.